Back to mobile site

Regeneron Pharma (REGN) Price Target Raised to $410 at RBC

November 4, 2014 3:28 PM EST Send to a Friend
RBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $410.00 (from $373.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login